Trastuzumab Deruxtecan Outperforms Standard of Care in Second-line HER2+ Breast Cancer - OncLive
6/1/2022 12:00:00 AM2 years 11 months ago
by Brittany Lovely
by Brittany Lovely
Heather McArthur, MD, MPH, described how the data from DESTINY-Breast03 reshapes the treatment landscape and offers added benefit to patients with brain metastases.
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu) continues to shake up the treatment landscape for patients with HER2positive metastatic breast cancer with the latest FDA approva… [+6922 chars]
full article...